Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
Surain B. Roberts, Marwa Ismail, Gowthami Kanagalingam, Andrew L. Mason, Mark G. Swain, Catherine Vincent, Eric M. Yoshida, Cynthia Tsien, Jennifer A. Flemming, Harry L.A. Janssen, Gideon M. Hirschfield, Bettina E. Hansen, Aliya F. Gulamhusein, the Canadian Network for Autoimmune Liver Disease – 6 July 2020 – Patients with primary biliary cholangitis (PBC) with incomplete response to ursodeoxycholic acid are at risk of disease progression and need additional therapy.